论文部分内容阅读
a-干扰素(IFN-a)是目前临床最常用的治疗乙型肝炎的药物之一,它主要通过JAK-STAT信号转导通路诱导靶细胞产生抗病毒蛋白和免疫调节作用来抑制并清除乙型肝炎(HBV)。但临床上约有2/3的患者对IFN-a治疗无反应,使得应用IFN-a治疗HBV受到局限。现就此对HBV抵抗IFN-a作用机制的最新研究进行作一综述。
Alpha-interferon (IFN-a) is one of the most commonly used clinically used drugs for the treatment of Hepatitis B. It inhibits and clears B by mainly inducing target cells to produce anti-viral proteins and immunomodulatory effects via the JAK-STAT signaling pathway Hepatitis B (HBV). However, about two-thirds of patients in the clinical trial did not respond to the IFN-a treatment, which limited the use of IFN-α in the treatment of HBV. In this regard, the latest study on the mechanism of HBV resistance to IFN-a is reviewed.